Rilvegostomig用于非小细胞肺癌的III 期研究｜NCT06868277

一分钟看懂

这是一项关于非小细胞肺癌的III 期研究，登记的药物或干预包括Rilvegostomig；Pembrolizumab，当前状态为招募中。登记地点显示中国保定、北京、蚌埠、长春等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。

Rilvegostomig；Pembrolizumab · III 期

登记的基本范围为不限性别，年龄18 岁；另列出8项专业入选条件，需结合英文原文并由研究团队确认。

登记记录列出8项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。

以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。

* Histologically or cytologically documented NSCLC (non small lung cancer), including all histological subtypes.
* Stage IV mNSCLC (metastatic non-small cell lung cancer) (based on the American Joint Committee on Cancer Edition 8) not amenable to curative treatment.
* Absence of sensitizing EGFR (epidermal growth factor) mutations and ALK (anaplastic lymphoma kinase) and ROS1 (c-ros oncogene 1) rearrangements. Negative assay result is required for all non-squamous histology subtypes.
* Absence of documented tumor genomic mutation results from tests conducted as part of standard local practice in any other actionable driver oncogenes for which there are locally approved targeted 1L (first line) therapies.
* WHO (World Health Organization)/ECOG (Eastern Cooperative Oncology Group) performance status of 0 or 1, with no deterioration over the previous 2 weeks prior to baseline at screening and prior to randomization.
* Minimum life expectancy of 12 weeks.
* Provision of acceptable tumor sample for the central testing prior to randomization.
* At least one lesion not previously irradiated that qualifies as a RECIST 1.1 (Response Evaluation Criteria in Solid Tumors, Version 1.1) TL (target lesion) at baseline and can be accurately measured at baseline as ≥ 10 mm in the longest diameter (except lymp

请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。

登记号：NCT06868277；登记信息更新于 2026-09-25。